School of Pharmacy, Faculty of Health and Medical Science, Taylor's University, Subang Jaya, Selangor, Malaysia.
Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.
Curr Pharm Des. 2019;25(26):2828-2841. doi: 10.2174/1381612825666190716102037.
Adenosine is a ubiquitous signaling nucleoside molecule, released from different cells within the body to act on vasculature and immunoescape. The physiological action on the proliferation of tumour cell has been reported by the presence of high concentration of adenosine within the tumour microenvironment, which results in the progression of the tumour, even leading to metastases. The activity of adenosine exclusively depends upon the interaction with four subtypes of heterodimeric G-protein-coupled adenosine receptors (AR), A1, A2A, A2B, and A3-ARs on the cell surface. Research evidence supports that the activation of those receptors via specific agonist or antagonist can modulate the proliferation of tumour cells. The first category of AR, A1 is known to play an antitumour activity via tumour-associated microglial cells to prevent the development of glioblastomas. A2AAR are found in melanoma, lung, and breast cancer cells, where tumour proliferation is stimulated due to inhibition of the immune response via inhibition of natural killer cells cytotoxicity, T cell activity, and tumourspecific CD4+/CD8+ activity. Alternatively, A2BAR helps in the development of tumour upon activation via upregulation of angiogenin factor in the microvascular endothelial cells, inhibition of MAPK and ERK 1/2 phosphorylation activity. Lastly, A3AR is expressed in low levels in normal cells whereas the expression is upregulated in tumour cells, however, agonists to this receptor inhibit tumour proliferation through modulation of Wnt and NF-κB signaling pathways. Several researchers are in search for potential agents to modulate the overexpressed ARs to control cancer. Active components of A2AAR antagonists and A3AR agonists have already entered in Phase-I clinical research to prove their safety in human. This review focused on novel research targets towards the prevention of cancer progression through stimulation of the overexpressed ARs with the hope to protect lives and advance human health.
腺苷是一种普遍存在的信号核苷分子,从体内的不同细胞释放出来,作用于血管系统和免疫逃避。在肿瘤微环境中存在高浓度的腺苷,报道了其对肿瘤细胞增殖的生理作用,这导致了肿瘤的进展,甚至导致转移。腺苷的活性完全取决于其与细胞表面的四种异二聚体 G 蛋白偶联腺苷受体(AR)亚型 A1、A2A、A2B 和 A3-AR 的相互作用。研究证据表明,通过特定的激动剂或拮抗剂激活这些受体可以调节肿瘤细胞的增殖。第一类 AR,A1 被认为通过肿瘤相关的小胶质细胞发挥抗肿瘤活性,以防止神经胶质瘤的发展。A2AAR 存在于黑色素瘤、肺癌和乳腺癌细胞中,由于通过抑制自然杀伤细胞的细胞毒性、T 细胞活性和肿瘤特异性 CD4+/CD8+活性来抑制免疫反应,肿瘤增殖受到刺激。相反,A2BAR 通过在微血管内皮细胞中上调血管生成素因子的激活,抑制 MAPK 和 ERK 1/2 磷酸化活性,有助于肿瘤的发展。最后,A3AR 在正常细胞中低表达,而在肿瘤细胞中表达上调,然而,该受体的激动剂通过调节 Wnt 和 NF-κB 信号通路抑制肿瘤增殖。一些研究人员正在寻找潜在的调节剂来调节过表达的 AR 以控制癌症。A2AAR 拮抗剂和 A3AR 激动剂的活性成分已经进入 I 期临床研究,以证明其在人体中的安全性。本综述重点介绍了通过刺激过表达的 AR 来预防癌症进展的新研究靶点,希望能保护生命并促进人类健康。